Login / Signup

Central Serous Chorioretinopathy: Pathogenesis and Management.

Francesco SemeraroFrancesco MorescalchiAndrea RussoElena GambicortiAndrea PilottoFrancesco ParmeggianiSilvia BartollinoCiro Costagliola
Published in: Clinical ophthalmology (Auckland, N.Z.) (2019)
Central serous chorioretinopathy (CSC) is a common retina disease and has a relative high recurrence rate, etiology, and pathogenesis of which remains largely ambiguous. The effects on the retina are usually self-limited, although some people are left with permanent vision loss due to progressive and irreversible photoreceptor damage or retinal pigment epithelium atrophy. There have been a number of interventions used in CSC, including, but not limited to, laser treatment, photodynamic therapy (PDT), intravitreal injection of anti-vascular endothelial growth factor agents, and subthreshold lasers. It is not clear whether there is a clinically important benefit to treating acute CSC, which often resolves spontaneously as part of its natural history. Of the interventions studied to date, PDT and micropulse laser treatment appear the most promising. .
Keyphrases
  • photodynamic therapy
  • vascular endothelial growth factor
  • high grade
  • diabetic retinopathy
  • physical activity
  • oxidative stress
  • endothelial cells
  • combination therapy
  • high speed
  • respiratory failure
  • drug induced